According to IQVIA sales data for the 12-month period ended May 2026, the reference product recorded annual sales of approximately $25.4 million in the US.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “The launch of Olanzapine for Injection underscores our strategic focus on growing a robust injectable portfolio and strengthening our presence within the institutional channel. It reflects our continued commitment to expanding access to quality and affordable treatment options to meet the evolving needs of patients and healthcare providers.”

Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets.

The company reported a 6,381.9% increase in consolidated net profit to Rs 301.41 crore on a 16.8% increase in revenue from operations to Rs 3,760.28 crore in Q4 FY26, compared with Q4 FY25.